Clinical trials: MDS (Myelodysplastic Syndrome)
Myelodysplastic Syndromes
A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care
The purpose of this study is to determine whether patients with high-risk myelodysplastic syndromes (MDS) treated with azacitidine have improved survival compared to conventional care treatments.
- Trial name
- NCT00071799
- Testing
- Azacitidine, Physician Choice
- Where
- 108 sites in United States, Australia and 13 more
- Volunteers
- 358 people
- Sponsor
- Celgene
Myelodysplastic Syndrome, Acute Myeloid Leukemia
Phase II Part 2 Expansion of Oral Rigosertib in Combination With Azacitidine
This study, is a Phase I/II clinical trial in three parts: Phase I Dose Escalation, Phase II, Part 1 RPTD Cohort, and Phase II, Part 2 Expansion. The first two parts have been completed.
- Conditions
- Myelodysplastic Syndrome, Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia
- Trial name
- NCT01926587
- Testing
- oral rigosertib, Azacitidine
- Where
- 13 sites in United States, France
- Volunteers
- 45 people
- Sponsor
- Traws Pharma, Inc.
Acute Leukemia, Myelodysplastic Syndromes
A Study of ONO-7475 in Patients With Acute Leukemias
[Updated]: To assess the safety and tolerability of ONO-7475 monotherapy in patients with relapsed or refractory acute myeloid leukemia or relapsed or refractory myelodysplastic syndromes and to assess: i) safety and tolerability…
- Trial name
- NCT03176277
- Testing
- ONO-7475 3mg once daily, ONO-7475 6mg once daily, ONO-7475 10mg once daily
- Where
- 16 sites in United States
- Volunteers
- 42 people
- Sponsor
- Ono Pharmaceutical Co., Ltd.
Previously Treated Myelodysplastic Syndromes
CPI-613 in Treating Patients With Myelodysplastic Syndromes Who Failed Previous Therapy
This pilot clinical trial studies 6, 8-bis (benzylthio) octanoic acid (CPI-613) in treating patients with myelodysplastic syndromes who failed previous therapy.
- Trial name
- NCT01902381
- Testing
- 6,8-bis(benzylthio)octanoic acid
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Wake Forest University Health Sciences
Myelodysplastic Syndrome, Acute Myeloid Leukemia
A Phase Ib Study of Rezatapopt in Combination With Azacitidine in Patients With TP53Y220C Mutant Myeloid Malignancies (Acute Myeloid Leukemia or Myelodysplastic Syndrome)
A non-randomized phase Ib study of PC14586 (PMV therapeutics) in patients diagnosed with TP53Y220C-mutant myeloid malignancies, including AML and MDS.
- Trial name
- NCT06616636
- Testing
- Azacitidine, Rezatapopt
- Where
- 2 sites in United States
- Volunteers
- 24 people
- Sponsor
- M.D. Anderson Cancer Center
Acute Myeloid Leukemia, Myelodysplasia
Haploidentical Stem Cell Transplant With or Without NK Cell Infusion in AML and MDS
Relapse after an allogeneic hematopoietic stem cell transplantation (HSCT) is high in patients with advanced AML, in the 50% range.
- Trial name
- Bigeminy (NCT04166929)
- Testing
- Haplo SCT with NK cells, Haplo SCT
- Where
- Italy
- Volunteers
- 6 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
C3 Glomerulopathy (C3G), Paroxysmal Nocturnal Hemoglobinuria (PNH)
Managed Access Programs for LNP023, Iptacopan
The purpose of this registration form is to list all Managed Access Programs (MAPs) related to LNP023, Iptacopan
- Trial name
- NCT05222412
- Testing
- Iptacopan
- Sponsor
- Novartis Pharmaceuticals
Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia
Clinical Transplant-Related Long-term Outcomes of Alternative Donor Allogeneic Transplantation (BMT CTN 1702)
The purpose of this study is to determine if a search strategy of searching for an HLA-matched unrelated donor for allogeneic transplantation if possible then an alternative donor if an HLA-matched unrelated donor is not…
- Conditions
- Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndromes, Non-hodgkin Lymphoma
- Trial name
- BMT CTN 1702 (NCT03904134)
- Testing
- Donor Search Prognosis Score
- Where
- 52 sites in United States
- Volunteers
- 1,753 people
- Sponsor
- Center for International Blood and Marrow Transplant Research
Paroxysmal Nocturnal Hemoglobinuria
A Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Patients With PNH
Evaluation of the Efficacy and Safety of Pegcetacoplan in Patients with Paroxysmal Nocturnal Hemoglobinuria .
- Trial name
- NCT04085601
- Testing
- APL-2
- Where
- 30 sites in Colombia, Hong Kong and 8 more
- Volunteers
- 53 people
- Sponsor
- Apellis Pharmaceuticals, Inc.
Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS)
Antigen-specific T Cell Therapy for AML or MDS Patients With Relapsed Disease After Allo-HCT
This Research study is being done to characterize the safety, tolerability, and preliminary antitumor activity of the NEXI-001 T cell product (a new experimental therapy), which contains populations of CD8+ T cells targeting…
- Trial name
- NCT04284228
- Testing
- Infusion of NEXI-001 T Cells
- Where
- 5 sites in United States
- Volunteers
- 22 people
- Sponsor
- NexImmune Inc.
Paroxysmal Nocturnal Hemoglobinuria (PNH)
A Study of Single and Multiple Doses of LP-005 in Healthy Adult Participants
The purpose of this study is to evaluate safety, tolerability, immunogenicity, pharmacokinetics, pharmacodynamics, and efficacy of LP-005 in healthy volunteers.
- Trial name
- NCT06294301
- Testing
- LP-005 Dose 1 (Single), LP-005 Dose 2 (Single), LP-005 Dose 3 (Single)
- Where
- China
- Volunteers
- 68 people, healthy volunteers welcome
- Sponsor
- Longbio Pharma
Acute Myeloid Leukemia, Myelodysplastic Syndrome
Quizartinib, Decitabine, and Venetoclax in Treating Participants With Untreated or Relapsed Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome
This phase I/II trial studies how well quizartinib, decitabine, and venetoclax work in treating participants with acute myeloid leukemia or high risk myelodysplastic syndrome that is untreated or has come back (relapsed).
- Conditions
- Acute Myeloid Leukemia, Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia, Recurrent Myelodysplastic Syndrome
- Trial name
- NCT03661307
- Testing
- Decitabine, Quizartinib, Venetoclax
- Where
- United States
- Volunteers
- 129 people
- Sponsor
- M.D. Anderson Cancer Center
Chronic Myelogenous Leukemia (CML), Acute Myelogenous Leukemia (AML)
Unrelated Umbilical Cord Blood (UBC)Transplantation
Hematopoietic progenitor cell (HPC- primitive cells in the blood, bone marrow and umbilical cord that can restore the bone marrow) transplant can be a curative therapy for the treatment of hematologic malignancies (a disease of…
- Conditions
- Chronic Myelogenous Leukemia (CML), Acute Myelogenous Leukemia (AML), Myelodysplastic Syndrome, Multiple Myeloma
- Trial name
- NCT01768845
- Testing
- umbilical cord blood (UCB)
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- West Virginia University
Acute Leukaemia, Myelodysplastic Syndrome
Natural Killer Cells in Acute Leukaemia and Myelodysplastic Syndrome
A novel method has been developed to expand natural (NK) cells and enhance their cytotoxicity against cancer cells while maintaining low killing capacity against non-transformed cells.
- Trial name
- NCT02123836
- Testing
- NK cells
- Where
- Singapore
- Volunteers
- 20 people
- Sponsor
- National University Hospital, Singapore
Myelodysplastic Syndrome (MDS)
Study of Vidaza (Azacitidine) Versus Support Treatment in Patients With Low Risk Myelodysplastic Syndrome (Low and Intermediate-1 IPSS) Without the 5q Deletion and Transfusion Dependent Anaemia
Primary Outcome Measures: To evaluate the efficacy of treatment with Azacitidine in patients with transfusion-dependent, low risk International Prognostic Scoring System (IPSS) 0 int-1, Myelodysplastic Syndrome (MDS) without…
- Trial name
- ABRAZA (NCT01338337)
- Testing
- Azacitidine
- Where
- 9 sites in Spain
- Volunteers
- 40 people
- Sponsor
- Asociación Andaluza de Hematología y Hemoterapia
Leukemia, Lymphoma
Pentostatin and Alemtuzumab as a Preparative Regimen for Allogeneic Peripheral Blood Stem Cell Transplantation
This study tests the hypothesis that a purely immunosuppressive preparative regimen allows engraftment of related or unrelated allogeneic hematopoietic stem cells in subjects with high-risk malignancies, without causing the…
- Conditions
- Leukemia, Lymphoma, Hodgkin's Disease, Hematologic Neoplasms
- Trial name
- NCT00698685
- Testing
- Pentostatin, Alemtuzumab, Allogeneic hematopoietic stem cell transplantation
- Where
- 2 sites in United States
- Volunteers
- 14 people
- Sponsor
- University of Arizona
Acute Biphenotypic Leukemia, Acute Lymphoblastic Leukemia
Management of Platelet Transfusion Therapy in Patients With Blood Cancer or Treatment-Induced Thrombocytopenia
This pilot clinical trial compares the safety of two different platelet transfusion "thresholds" among patients with blood cancer or treatment-induced thrombocytopenia whose condition requires anticoagulant medication (blood…
- Conditions
- Acute Biphenotypic Leukemia, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, B-Cell Non-Hodgkin Lymphoma
- Trial name
- NCT03195010
- Testing
- Platelet Transfusion
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Fred Hutchinson Cancer Center
Primary MDS (Very Low, Low or Intermediate IPSS-R With <5% Blasts), Anemia
Efficacy and Safety of Roxadustat for Treatment of Anemia in Participants With Lower Risk Myelodysplastic Syndrome With Low Red Blood Cell Transfusion Burden
The purpose of this study is to determine whether FG-4592 is safe and effective in the treatment of anemia in participants with lower risk MDS and low red blood cell transfusion burden.
- Trial name
- NCT03263091
- Testing
- Roxadustat
- Where
- 124 sites in United States, Australia and 14 more
- Volunteers
- 184 people
- Sponsor
- Kyntra Bio
Myelodysplastic Syndromes (MDS)
Asia Myelodysplastic Syndrome (MDS) Registry
The purpose of this study is to provide a contemporary view and offer invaluable insights into the demographic profiles, clinical characteristics, treatments, and real-world outcomes of individuals with myelodysplastic syndromes…
- Trial name
- NCT07355478
- Testing
- Prescribed treatments for myelodysplastic syndromes (MDS)
- Where
- 3 sites in Singapore, South Korea and 1 more
- Volunteers
- 500 people
- Sponsor
- Bristol-Myers Squibb
Myelodysplastic Syndromes
Hetrombopag for Lower-risk MDS With Thrombocytopenia: a Prospective，Open-label, Single-arm Study.
The is a phase 2, single-arm, open-label clinical study assessing the efficacy and safety of hetrombopag to increase platelet count in lower-risk MDS patients with thrombocytopenia.
- Trial name
- NCT05392647
- Testing
- Hetrombopag
- Volunteers
- 28 people
- Sponsor
- Tongji Hospital